MX2019013184A - Dominios de union a anti-cd3 y anticuerpos que los comprenden, y metodos para su generacion y uso. - Google Patents

Dominios de union a anti-cd3 y anticuerpos que los comprenden, y metodos para su generacion y uso.

Info

Publication number
MX2019013184A
MX2019013184A MX2019013184A MX2019013184A MX2019013184A MX 2019013184 A MX2019013184 A MX 2019013184A MX 2019013184 A MX2019013184 A MX 2019013184A MX 2019013184 A MX2019013184 A MX 2019013184A MX 2019013184 A MX2019013184 A MX 2019013184A
Authority
MX
Mexico
Prior art keywords
antibodies
methods
binding domains
generation
potency
Prior art date
Application number
MX2019013184A
Other languages
English (en)
Spanish (es)
Inventor
Krauland Eric
Vasquez Maximiliano
M Walker Laura
Pejchal Robert
Wai Ling Leung Monica
Original Assignee
Adimab Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adimab Llc filed Critical Adimab Llc
Publication of MX2019013184A publication Critical patent/MX2019013184A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2019013184A 2017-05-08 2018-05-08 Dominios de union a anti-cd3 y anticuerpos que los comprenden, y metodos para su generacion y uso. MX2019013184A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762503315P 2017-05-08 2017-05-08
PCT/US2018/031705 WO2018208864A1 (en) 2017-05-08 2018-05-08 Anti-cd3-binding domains and antibodies comprising them, and methods for their generation and use

Publications (1)

Publication Number Publication Date
MX2019013184A true MX2019013184A (es) 2020-02-07

Family

ID=64104990

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019013184A MX2019013184A (es) 2017-05-08 2018-05-08 Dominios de union a anti-cd3 y anticuerpos que los comprenden, y metodos para su generacion y uso.
MX2024005009A MX2024005009A (es) 2017-05-08 2019-11-05 Dominios de union anti-cd3 y anticuerpos que los comprenden, y metodos para su generacion y uso.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2024005009A MX2024005009A (es) 2017-05-08 2019-11-05 Dominios de union anti-cd3 y anticuerpos que los comprenden, y metodos para su generacion y uso.

Country Status (12)

Country Link
US (2) US11542330B2 (enExample)
EP (1) EP3621641A4 (enExample)
JP (3) JP7393207B2 (enExample)
KR (2) KR20250121461A (enExample)
CN (4) CN118894936A (enExample)
AU (2) AU2018266711B2 (enExample)
BR (1) BR112019023111A2 (enExample)
CA (1) CA3062825A1 (enExample)
IL (2) IL322042A (enExample)
MX (2) MX2019013184A (enExample)
SG (2) SG11201910096RA (enExample)
WO (1) WO2018208864A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021014973A (es) * 2019-06-07 2022-04-18 Adimab Llc Anticuerpos anti-cd3 de alta afinidad y metodos para su generacion y uso.
CN119874917A (zh) * 2019-06-07 2025-04-25 阿迪马布有限责任公司 工程化的pH依赖性抗CD3抗体及其产生和使用方法
US20220227887A1 (en) * 2019-06-11 2022-07-21 Ono Pharmaceutical Co., Ltd. Immunosuppressant
JP2022544405A (ja) 2019-08-15 2022-10-18 アイジーエム バイオサイエンシズ インコーポレイテッド 免疫刺激性多量体型結合分子
KR20220045030A (ko) * 2019-08-17 2022-04-12 아이쥐엠 바이오사이언스 인코포레이티드 다량체성 이중특이적 항-cd123 결합 분자 및 이의 용도
US20210087271A1 (en) * 2019-09-20 2021-03-25 Adimab, Llc Fc variants with reduced effector function
AU2020403913B2 (en) 2019-12-18 2024-10-10 F. Hoffmann-La Roche Ag Bispecific anti-CCL2 antibodies
WO2021154534A1 (en) * 2020-01-28 2021-08-05 Promab Biotechnologies, Inc. Plap-cd3 epsilon bispecific antibodies
MX2022013499A (es) * 2020-04-27 2023-01-16 Twist Bioscience Corp Bibliotecas de ácidos nucleicos variantes para coronavirus.
CN111826400A (zh) * 2020-07-21 2020-10-27 中科宝承生物医学科技有限公司 一种双特异性抗体nk细胞制备方法及其细胞和应用
US20230374162A1 (en) * 2020-10-07 2023-11-23 Amgen Inc. Rational selection of building blocks for the assembly of multispecific antibodies
CN114539415B (zh) * 2020-11-24 2024-02-02 普米斯生物技术(珠海)有限公司 一种抗PD-L1/VEGF/TGF-β多特异性抗体及其用途
CN112578117B (zh) * 2021-02-22 2021-05-25 信纳克(北京)生化标志物检测医学研究有限责任公司 抗体组合物及其筛查移植后淋巴细胞增殖性疾病的应用
CN112698044B (zh) * 2021-03-23 2021-06-22 信纳克(北京)生化标志物检测医学研究有限责任公司 靶向治疗后免疫状态评价装置及方法
EP4380631A4 (en) * 2021-08-04 2025-06-25 Abpro Corporation Cd3 targeting antibodies and uses thereof
EP4377360A4 (en) * 2021-09-17 2025-10-15 Adimab Llc Anti-cd3 antibodies
EP4413044A4 (en) * 2021-10-07 2025-10-22 Nat Res Council Canada ANTI-CD3 MONOCLONAL ANTIBODIES AND THERAPEUTIC CONSTRUCTS
WO2023060277A1 (en) * 2021-10-08 2023-04-13 Arbele Limited Composition of multispecific antibodies targeting cdh17-expressing tumors and method of making and using thereof
CN114573705B (zh) * 2022-03-17 2024-05-14 杭州师范大学 特异性启动抗乙型肝炎病毒t细胞免疫的双特异性抗体及其应用
CN114605560B (zh) * 2022-03-30 2024-02-20 江苏蒙彼利生物科技有限公司 一种car-nk细胞及其制备方法与应用
CN116925232A (zh) * 2022-04-02 2023-10-24 普米斯生物技术(珠海)有限公司 靶向ceacam和cd3的多特异性抗体及其用途
CN115453124B (zh) * 2022-08-01 2025-11-25 中国科学院高能物理研究所 一种纳米颗粒表面多层蛋白冠成分的原位鉴定与定量方法
WO2024102948A1 (en) 2022-11-11 2024-05-16 Celgene Corporation Fc receptor-homolog 5 (fcrh5) specific binding molecules and bispecific t-cell engaging antibodies including same and related methods
CN115960243B (zh) * 2023-01-09 2025-05-06 中国药科大学 靶向cd24和cd3的双特异性抗体及其应用
WO2024206568A2 (en) * 2023-03-31 2024-10-03 Ibio, Inc. Anti-cd3 antibodies
WO2025230233A1 (ko) * 2024-05-03 2025-11-06 국민대학교산학협력단 인간 cd3에 특이적인 항체 및 이의 용도
WO2026006495A1 (en) 2024-06-25 2026-01-02 Alloy Therapeutics, Inc. Anti-wt1/hla-a2 antibody and uses thereof
WO2026006492A2 (en) 2024-06-25 2026-01-02 Ypsilon Therapeutics, Inc. Anti-prame/hla-a2 antibodies and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1629011T3 (da) * 2003-05-31 2010-05-03 Micromet Ag Humane anti-humane-DC3-bindingsmolekyler
CA2569509C (en) 2004-06-03 2014-08-12 Novimmune S.A. Anti-cd3 antibodies and methods of use thereof
SG182408A1 (en) * 2010-01-11 2012-08-30 Alexion Pharma Inc Biomarkers of immunomodulatory effects in humans treated with anti-cd200 antibodies
WO2012158818A2 (en) * 2011-05-16 2012-11-22 Fabion Pharmaceuticals, Inc. Multi-specific fab fusion proteins and methods of use
EP2760891B1 (en) * 2011-09-26 2018-11-07 JN Biosciences LLC Hybrid constant regions
HUE037720T2 (hu) * 2012-03-28 2018-09-28 Sanofi Sa Bradikinin B1 receptor ligandumok elleni antitestek
ME03675B (me) * 2013-07-05 2020-10-20 Genmab As Humanizovana ili himerna anтi-cd3 antiтela
IL263466B2 (en) * 2013-12-17 2023-10-01 Genentech Inc Anti-CD3 antibodies and methods of using them
PT3221356T (pt) * 2014-11-20 2020-10-29 Hoffmann La Roche Moléculas de ligação ao antigénio biespecíficas ativadoras das células t contra folr1 e cd3
CN120988137A (zh) * 2015-01-23 2025-11-21 赛诺菲 抗cd3抗体、抗cd123抗体和与cd3和/或cd123特异性结合的双特异性抗体
EP3091032A1 (en) * 2015-05-08 2016-11-09 Miltenyi Biotec GmbH Humanized antibody or fragment thereof specific for cd3

Also Published As

Publication number Publication date
BR112019023111A2 (pt) 2020-07-28
RU2019139334A (ru) 2021-06-09
AU2025203086A1 (en) 2025-07-24
JP2020518650A (ja) 2020-06-25
CN110913895B (zh) 2024-04-02
CA3062825A1 (en) 2018-11-15
MX2024005009A (es) 2024-05-10
SG11201910096RA (en) 2019-11-28
US20200190189A1 (en) 2020-06-18
IL322042A (en) 2025-09-01
RU2019139334A3 (enExample) 2021-08-25
EP3621641A4 (en) 2021-03-03
CN110913895A (zh) 2020-03-24
KR102844399B1 (ko) 2025-08-11
KR20250121461A (ko) 2025-08-12
IL270366B2 (en) 2026-01-01
JP2023014324A (ja) 2023-01-26
AU2018266711A1 (en) 2019-11-28
KR20200053437A (ko) 2020-05-18
JP7393207B2 (ja) 2023-12-06
US20230151097A1 (en) 2023-05-18
IL270366A (en) 2019-12-31
US11542330B2 (en) 2023-01-03
CN118894936A (zh) 2024-11-05
WO2018208864A1 (en) 2018-11-15
CN118184781A (zh) 2024-06-14
CN118562001A (zh) 2024-08-30
AU2025203086A9 (en) 2026-03-05
AU2018266711B2 (en) 2025-02-06
JP2024032937A (ja) 2024-03-12
EP3621641A1 (en) 2020-03-18
JP7641262B2 (ja) 2025-03-06
SG10201912494TA (en) 2020-02-27
IL270366B1 (en) 2025-09-01

Similar Documents

Publication Publication Date Title
MX2019013184A (es) Dominios de union a anti-cd3 y anticuerpos que los comprenden, y metodos para su generacion y uso.
MX2021014966A (es) Anticuerpos anti-cd3 dependientes de ph modificados geneticamente y metodos para su generacion y uso.
MX2019010583A (es) Anticuerpos contra ligando 1 de muerte programada.
CL2018000378A1 (es) Receptores de antígenos quiméricos basados en anticuerpos de dominio simple y métodos de uso de estos
AR116173A1 (es) Agentes de unión a psma y usos de estos
MX2020006689A (es) Composiciones de vcar y metodos de uso.
CL2020001193A1 (es) Medios y método para preparar vectores virales y usos de los mismos.
CO2019003154A2 (es) Anticuerpos anti-pd-1 y sus usos
CO2018011804A2 (es) Receptores quiméricos de flt3 y métodos de uso de los mismos
BR112018014760A2 (pt) anticorpos anti-ror1, anticorpos biespecíficos para ror1 x cd3 e métodos de uso dos mesmos
PE20191812A1 (es) Compuestos y metodos para la reduccion celular especifica de tumor
MX2020010946A (es) Anticuerpos multiespecificos y usos del mismo.
CL2018003366A1 (es) Anticuerpos anti -cd40 y sus usos
CO2018000244A2 (es) Anticuerpos madurados por afinidad y humanizados para fcrh5
AR106574A1 (es) Anticuerpos biespecíficos con tetravalencia para un receptor de fnt coestimulador
AR114789A1 (es) Anticuerpos anti-hla-g y uso de los mismos
MX2021011816A (es) Metodos para produccion de celulas car-nk y uso de las mismas.
MX2019013001A (es) Expansion de celulas t gamma delta, sus composiciones y metodos de uso de las mismas.
AR112048A1 (es) Anticuerpos cd47 y métodos de uso de los mismos
CR20160314A (es) Anticuerpos anti-cd3 y metodos de uso
CR20220186A (es) ANTICUERPOS ANTI-TIGIT Y MÉTODOS DE USO (divisional 2018-0225)
MX2017016838A (es) Construcciones dirigidas a complejos de peptido de ny-eso-1/complejo principal de histocompatibilidad (mhc) y usos de los mismos.
CO2022008272A2 (es) Agentes de unión a ilt3 y métodos de uso de los mismos
MX376437B (es) Uso de hígado descelularizado por perfusión para recelularización de células de islote.
MX2021003654A (es) Metodo para seleccionar neoepitopes.